Search

Your search keyword '"Göbel, Carl H."' showing total 22 results
Start Over Author "Göbel, Carl H."
22 results on '"Göbel, Carl H."'

5. Adressen

Author

Bialas, Patric, primary, Sittig, Hans-Bernd, additional, Arriens, Peter, additional, Diel, Ingo J., additional, Draewe, Joachim, additional, Göbel, Carl H., additional, Göbel, Hartmut, additional, Gustorff, Burkhard, additional, Häuser, Winfried, additional, Heinze, Axel, additional, Heinze-Kuhn, Katja, additional, Hoffmann, Patrick, additional, Jansen, Jan-Peter, additional, Karst, Matthias, additional, Keiner, Dörthe, additional, Kieseritzky, Karin, additional, Köllner, Volker, additional, Khreish, Fadi, additional, Lindena, Gabriele, additional, Niewald, Marcus, additional, Rapior, Regina, additional, Wieden, Torsten, additional, Wirz, Stefan, additional, Zernikow, Boris, additional, Benrath, Justus, additional, Brons, Magdalene, additional, Ellinger, Klaus, additional, Fahl, Susanne, additional, Ganser, Gerd, additional, Illhardt, Arnold, additional, Kayser, Hubertus, additional, Naumann, Emil Günther, additional, Olenik, Daniela, additional, Quante, Markus, additional, Risack, Dirk, additional, Roth, Christoph, additional, Stegat, Martin, additional, Sycha, Thomas, additional, Hintzenstern, Ulrich von, additional, Weinschütz, Thomas, additional, Wieden, Bötersen, Marion, additional, Willenbrink, Hans-Joachim, additional, Wollmer, Michael, additional, and Zimmermann, Lutz, additional

Published
2022
Full Text
View/download PDF

7. Reply to the letter: Headaches during/after SARS‐CoV‐2 infection/vaccination can be primary and secondary as well as acute and chronic, by Finsterer J and Mehri S

Author

Mitsikostas, Dimos‐Dimtirios D., primary, Caronna, Edoardo, additional, De Tommaso, Marina, additional, Deligianni, Christina I., additional, Ekizoglu, Esme, additional, Bolay, Hayrunnisa, additional, Göbel, Carl H., additional, Kristoffersen, Espen Saxhaug, additional, Lampl, Christian, additional, Moro, Elena, additional, Pozo‐Rosich, Patricia, additional, Sellner, Johann, additional, Terwindt, Gisela, additional, and Irimia‐Sieira, Pablo, additional

Published
2024
Full Text
View/download PDF

8. Headaches and facial pain attributed to SARS‐CoV‐2 infection and vaccination: a systematic review

Author

Mitsikostas, Dimos‐Dimtirios D., primary, Caronna, Edoardo, additional, De Tommaso, Marina, additional, Deligianni, Christina I., additional, Ekizoglu, Esme, additional, Bolay, Hayrunnisa, additional, Göbel, Carl H., additional, Kristoffersen, Espen Saxhaug, additional, Lampl, Christian, additional, Moro, Elena, additional, Pozo‐Rosich, Patricia, additional, Sellner, Johann, additional, Terwindt, Gisela, additional, and Sieira, Pablo Irimia, additional

Published
2024
Full Text
View/download PDF

14. Explicit Diagnostic Criteria for Transient Ischemic Attacks Used in the Emergency Department Are Highly Sensitive and Specific

Author

Göbel, Carl H., Karstedt, Sarah C., Münte, Thomas F., Göbel, Hartmut, Wolfrum, Sebastian, Lebedeva, Elena R., Olesen, Jes, Royl, Georg, Göbel, Carl H., Karstedt, Sarah C., Münte, Thomas F., Göbel, Hartmut, Wolfrum, Sebastian, Lebedeva, Elena R., Olesen, Jes, and Royl, Georg

Abstract

Background: Making a correct diagnosis of a transient ischemic attack (TIA) is prone to errors because numerous TIA mimics exist and there is a shortage of evidence-based diagnostic criteria for TIAs. In this study, we applied for the first time the recently proposed explicit diagnostic criteria for transient ischemic attacks (EDCT) to a group of patients presenting to the emergency department of a large German tertiary care hospital with a suspected TIA. The aim was to determine the sensitivity and specificity of the EDCT in its clinical application. Methods: A total of 128 patients consecutively presenting to the emergency department of the University Hospital of Lübeck, Germany, under the suspicion of a TIA were prospectively interviewed about their clinical symptoms at the time of presentation. The diagnosis resulting from applying the EDCT was compared to the diagnosis made independently by the senior physicians performing the usual diagnostic work-up ("gold standard"), allowing calculation of sensitivity and specificity of the EDCT. Results: EDCT achieved a sensitivity of 96% and a specificity of 88%. When adding the additional criterion F ("the symptoms may not be better explained by another medical or mental disorder"), specificity significantly increased to 98%. Conclusions: The data show that the EDCT in its modified version as proposed by us are a highly useful tool for clinicians. They display a high sensitivity and specificity to accurately diagnose TIAs in patients referred to the emergency department with a suspected TIA.

Published
2021

15. Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study

Author

Göbel, Carl H, primary, Heinze, Axel, additional, Karstedt, Sarah, additional, Morscheck, Mascha, additional, Tashiro, Lilian, additional, Cirkel, Anna, additional, Hamid, Qutayba, additional, Halwani, Rabih, additional, Temsah, Mohamad-Hani, additional, Ziemann, Malte, additional, Görg, Siegfried, additional, Münte, Thomas, additional, and Göbel, Hartmut, additional

Published
2021
Full Text
View/download PDF

19. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine.

Author

Puledda, Francesca, Sacco, Simona, Diener, Hans-Christoph, Ashina, Messoud, Al-Khazali, Haidar M., Ashina, Sait, Burstein, Rami, Liebler, Eric, Cipriani, Andrea, Chu, Min Kyung, Cocores, Alexandra, Dodd-Glover, Freda, Ekizoğlu, Esme, Garcia-Azorin, David, Göbel, Carl H., Goicochea, Maria Teresa, Hassan, Amr, Hirata, Koichi, Hoffmann, Jan, and Jenkins, Bronwyn

Subjects
*MEDICATION overuse headache, *ACCEPTANCE & commitment therapy, *VAGUS nerve stimulation, *MEDICAL personnel, *ANGIOTENSIN-receptor blockers, *PRIMARY headache disorders, *MIGRAINE aura, *NEURAL stimulation, *ORAL medication
Abstract

This document published by the International Headache Society provides practical recommendations for the preventive pharmacological treatment of migraines. The recommendations are categorized into two levels: Optimal and Essential, based on medication availability in different regions. The document includes a table listing drugs with evidence of efficacy for migraine prevention and their availability in the World Health Organization Model List of Essential Medicines. The recommendations aim to establish essential standards of migraine management worldwide and provide guidance on evaluating treatment effectiveness, switching medications, combination therapy, and duration of treatment. The document also discusses comorbidities, specific medications for chronic migraine, preventive treatment in different populations, and managing medication overuse headache. [Extracted from the article]

Published
2024
Full Text
View/download PDF

21. [Acute Therapy of Migraine: What is new?]

Author

Heinze A, Heinze-Kuhn K, Göbel H, and Göbel CH

Subjects
Humans, Piperidines therapeutic use, Serotonin Receptor Agonists therapeutic use, Benzamides therapeutic use, Pyridines therapeutic use, Migraine Disorders therapy, Migraine Disorders drug therapy, Tryptamines therapeutic use
Abstract

The landscape of acute migraine medication has changed fundamentally in recent years. It has been a gradual, often unnoticed process characterized less by spectacular introduction of new substances than by changes in patients' access to medications and individualized selection of treatment adapted to the patients' needs. Four triptans are now available over-the-counter in Germany which has a major influence on self-medication. The main new introduction was the 5HT1F-agonist lasmiditan as an alternative to triptans., Competing Interests: AH erhielt Zuschüsse, nicht finanzielle Unterstützung und persönliche Honorare von Abbvie/Allergan, Grünenthal, Hormosan, Eli Lilly, Lundbeck, Novartis und TEVA Pharmaceutical. KHK erhielt Zuschüsse, nicht finanzielle Unterstützung und persönliche Honorare von Abbvie/Allergan, Hormosan, Eli Lilly, Lundbeck, Novartis und TEVA Pharmaceutical.HG erhielt Zuschüsse, nicht finanzielle Unterstützung und persönliche Honorare von Amgen, Abbvie/Allergan, Eli Lilly, Lundbeck, Novartis und TevaPharmaceutical. CG erhielt Zuschüsse, nicht finanzielle Unterstützung und persönliche Honorare von Abbvie/Allergan, Novartis und Teva Pharmaceutical., (Thieme. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results